In summary, the described IL-23 inhibitors have proven to be an effective and generally safe treatment for CD, with a potential to target this condition more specifically and successfully, especially in patients with refractory Crohn’s disease or those unresponsive to other biologics. This evidence concerns the gene IL23A and Cowden disease.